MedDataX Logo

Impact of Different Contraceptives on the Immune System of HIV Infected Women in Zambia

NCT ID: NCT00807625

Last Updated: 2012-07-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, 66 HIV-infected women who desire contraception will be randomly assigned to use either an IUD or Depo Provera, and will be followed for six months. The study is intended to help investigators understand potential mechanisms by which hormonal contraception may hasten HIV disease progression.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this randomized controlled trial, 66 HIV-infected women who desire contraception will be assigned to one of two treatment groups: IUD or Depo Provera. The study builds on findings from a previous study which examined the safety and acceptability of hormonal contraception and IUD among HIV-infected women. Secondary analyses from the previous study indicated that women who were assigned to the hormonal arm appeared to have faster disease progression based on death and decline in CD4+ count as compared to women assigned to the IUD arm. With the current study, investigators seek to understand potential mechanisms for the effect of hormonal contraception on hastening HIV disease progression. Enrolled women will be asked to use the assigned contraception method for a period of six months, and various indicators of disease progression will be collected at four follow-up visits after randomization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Contraception HIV Infections

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HIV/AIDS Contraception Birth control CD4+ Viral Load T-cell activation B-cell activation Hormonal Intrauterine device Depo Provera Women IUCD treatment naive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IUCD

Assigned to use a copper intrauterine device

Group Type ACTIVE_COMPARATOR

Copper T Intrauterine contraception device

Intervention Type DEVICE

IUCD inserted upon randomization to this study arm

DMPA

Assigned to use Depo Provera

Group Type ACTIVE_COMPARATOR

Depo Provera

Intervention Type DRUG

Depo Provera administered by injection at randomization visit and the 12-week study visit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Depo Provera

Depo Provera administered by injection at randomization visit and the 12-week study visit.

Intervention Type DRUG

Copper T Intrauterine contraception device

IUCD inserted upon randomization to this study arm

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ParaGuard TCu 380A

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed HIV status by local rapid test algorithm
* Willingness to be randomized to a contraceptive method and continue that method for at least 6 months.
* Intention to stay in the study area for at least 6 months

Exclusion Criteria

* Currently pregnant or pregnant within the prior 6 months
* Currently breastfeeding
* Documented liver disease
* History of coagulation disorder
* Active tuberculosis
* Anemia, defined as Hgb \<8gm/dL
* Age \< 16 years (the age of consent in Zambia);
* Eligible for antiretroviral therapy based on Zambian National Guidelines (CD4+ \< 200, or WHO stage IV, or CD4+\< 350 and WHO stage III)
* Currently using an IUD or hormonal method of contraception, or have used a hormonal contraceptive in the past 6 months
Minimum Eligible Age

16 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Alabama at Birmingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elizabeth M Stringer, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Centre for Infectious Disease Research in Zambia

Lusaka, Lusaka Province, Zambia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Zambia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

F071227004

Identifier Type: -

Identifier Source: org_study_id